Noninvasive fetal RhD genotyping.

摘要: Immunization against RhD is the major cause of hemolytic disease fetus and newborn (HDFN), which causes fetal or neonatal death. The introduction postnatal immune prophylaxis in 1960s drastically reduced immunization incidents pregnant, D-negative women. In several countries, antenatal combined with to further minimize risk. Due lack knowledge type, given all European population, approximately 40% pregnant women carry a are thus at no risk immunization. Noninvasive genotyping enables be targeted only those carrying D-positive avoid unnecessary treatment. Based on an analysis cell-free DNA from plasma women, this approach has recently undergone technical improvements rapid clinical implementation. As screening assay, sensitivity >99.3% gestational age 10-11 weeks. addition, widely used assess HDFN anti-D immunized